Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2014

Open Access 01-12-2014 | Research article

A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer

Authors: Shannon Cope, Jie Zhang, Stephen Saletan, Brielan Smiechowski, Jeroen P Jansen, Peter Schmid

Published in: BMC Medicine | Issue 1/2014

Login to get access

Abstract

Background

The aim of this study is to outline a general process for assessing the feasibility of performing a valid network meta-analysis (NMA) of randomized controlled trials (RCTs) to synthesize direct and indirect evidence for alternative treatments for a specific disease population.

Methods

Several steps to assess the feasibility of an NMA are proposed based on existing recommendations. Next, a case study is used to illustrate this NMA feasibility assessment process in order to compare everolimus in combination with hormonal therapy to alternative chemotherapies in terms of progression-free survival for women with advanced breast cancer.

Results

A general process for assessing the feasibility of an NMA is outlined that incorporates explicit steps to visualize the heterogeneity in terms of treatment and outcome characteristics (Part A) as well as the study and patient characteristics (Part B). Additionally, steps are performed to illustrate differences within and across different types of direct comparisons in terms of baseline risk (Part C) and observed treatment effects (Part D) since there is a risk that the treatment effect modifiers identified may not explain the observed heterogeneity or inconsistency in the results due to unexpected, unreported or unmeasured differences. Depending on the data available, alternative approaches are suggested: list assumptions, perform a meta-regression analysis, subgroup analysis, sensitivity analyses, or summarize why an NMA is not feasible.

Conclusions

The process outlined to assess the feasibility of an NMA provides a stepwise framework that will help to ensure that the underlying assumptions are systematically explored and that the risks (and benefits) of pooling and indirectly comparing treatment effects from RCTs for a particular research question are transparent.
Appendix
Available only for authorised users
Literature
1.
Bafeta A, Trinquart L, Seror R, Ravaud P: Analysis of the systematic reviews process in reports of network meta-analyses: methodological systematic review. BMJ. 2013, 347: f3675.CrossRefPubMedPubMedCentral
2.
3.
Cooper NJ, Sutton AJ, Morris D, Ades AE, Welton NJ: Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Stat Med. 2009, 28: 1861-1881.CrossRefPubMed
4.
Dias S, Sutton AJ, Ades AE, Welton NJ: Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013, 33: 607-617.CrossRefPubMedPubMedCentral
5.
Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, Lee K, Boersma C, Annemans L, Cappelleri J: Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011, 14: 429-437.CrossRefPubMed
6.
Jansen JP, Naci H: Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med. 2013, 11: 159.CrossRefPubMedPubMedCentral
7.
Gagnier JJ, Morgenstern H, Altman DG, Berlin J, Chang S, McCulloch P, Sun X, Moher D: Consensus-based recommendations for investigating clinical heterogeneity in systematic reviews. BMC Med Res Methodol. 2013, 13: 106.CrossRefPubMedPubMedCentral
8.
Ades AE: A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence. Stat Med. 2003, 22: 2995-3016.CrossRefPubMed
9.
Bucher HC, Guyatt GH, Griffith LE, Walter SD: The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997, 50: 683-691.CrossRefPubMed
10.
11.
Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, Boersma C, Thompson D, Larholt KM, Diaz M, Barrett A: Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011, 14: 429-437.CrossRefPubMed
12.
Lu G, Ades AE: Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004, 23: 3105-3124.CrossRefPubMed
13.
14.
Salanti G, Higgins JPT, Ades AE, Ioannidis JPA: Evaluation of networks of randomized trials. Stat Methods Med Res. 2008, 17: 279-301.CrossRefPubMed
15.
Achana FA, Cooper NJ, Dias S, Lu G, Rice SJ, Kendrick D, Sutton AJ: Extending methods for investigating the relationship between treatment effect and baseline risk from pairwise meta-analysis to network meta-analysis. Stat Med. 2013, 32: 752-771.CrossRefPubMed
16.
Dias S, Welton NJ, Caldwell DM, Ades AE: Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010, 29: 932-944.CrossRefPubMed
17.
Lu G, Ades AE: Assessing evidence inconsistency in mixed treatment comparisons. J Am Stat Assoc. 2006, 101: 447-4459.CrossRef
18.
White IF, Barrett JK, Jackson D, Higgens JP: Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Meth. 2012, 3: 111-125.CrossRef
19.
Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR: Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Meth. 2012, 3: 98-110.CrossRef
20.
Dias S, Sutton AJ, Welton NJ, Ades AE: Evidence synthesis for decision making 3: heterogeneity—subgroups, meta-regression, bias, and bias-adjustment. Med Decis Making. 2013, 33: 618.CrossRefPubMedPubMedCentral
21.
Greenland S, Morgenstern H: Ecological bias, confounding, and effect modification. Int J Epidemiol. 1989, 18: 269-274.CrossRefPubMed
22.
Berlin JA, Santanna J, Schmid CH, Szczech LA, Fedlman HI, Anti-Lymphocyte Antibody Induction Therapy Study Group: Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head. Stat Med. 2002, 21: 371-387.CrossRefPubMed
23.
24.
Baselga J, Campone C, Piccart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN: Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer. N Engl J Med. 2012, 366: 520-529.CrossRefPubMed
25.
Beaver JA, Park BH: The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncol. 2012, 8: 651-657.CrossRefPubMedPubMedCentral
26.
Piccart M, Noguchi S, Pritchard KI, Burris HA, Rugo HS, Gnant M, Hortobagyi GN, Melichar B, Petrakova K, Arena F, Xu C, Cahana A, Taran T, Sahmoud T, Lebwoh D, Campone M, Baselga J: Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 Phase III Trial. J Clin Oncol. 2012, 30: suppl; abstr 559
27.
Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS: Everolimus plus exemestane in postmenopausal patients with HR+ Breast Cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013, 30: 870-874.CrossRefPubMedPubMedCentral
28.
Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaeth D, Legouffe E, Allouache D, El Kouri C, Pujade-Lauraine E: Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012, 30: 2718-2724.CrossRefPubMed
29.
30.
National Institute for Health and Clinical Excellence: Everolimus in combination with exemestane for treating advanced HER2 negative hormone-receptor-positive breast cancer after endocrine therapy. Appraisal consultation document; March 2013. Available at: http://​guidance.​nice.​org.​uk/​TAG/​327/​FAD. Accessed 7 October 2013
31.
32.
33.
Jansen JP, Cope S: Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes. BMC Med Res Methodol. 2012, 12: 152.CrossRefPubMedPubMedCentral
34.
Saad ED, Katz A: Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined. Ann Oncol. 2009, 20: 460-464.CrossRefPubMed
35.
Ouwens MJ, Philips Z, Jansen JP: Network meta-analysis of parametric survival curves. Res Synth Meth. 2011, 1: 258-271.CrossRef
36.
37.
Spiegelhalter DJ, Best NG, Carlin BP, van der Linde A: Bayesian measures of model complexity and fit. J R Stat Soc (Series B). 2002, 64: 583-639.CrossRef
38.
Dempster AP: The direct use of likelihood for significance testing. Stat Comput. 1997, 7: 247-252.CrossRef
39.
Cope S, Ouwens MJ, Jansen JP, Schmid P: Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models. Value Health. 2013, 16: 403-417.CrossRefPubMed
40.
A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia. J Clin Oncol. 1986, 4: 186-193.
41.
Beuselinck B, Wildiers H, Wynendaele W, Dirix L, Kains JP, Paridaens R: Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: a randomized phase-II study of the Belgian Society of Medical Oncology. Crit Rev Oncol Hematol. 2010, 75: 70-77.CrossRefPubMed
42.
Bontenbal M, Andersson M, Wildiers J, Cocconi G, Jassem J, Paridaens R, Rotmensz N, Sylvester R, Mouridsen HT, Klijn JG, van Oosterom AT: Doxorubicin vs. epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group. Br J Cancer. 1998, 77: 2257-2263.CrossRefPubMedPubMedCentral
43.
Dixon AR, Jackson L, Chan S, Haybittle J, Blamey RW: A randomised trial of second-line hormone vs single agent chemotherapy in tamoxifen resistant advanced breast cancer. Br J Cancer. 1992, 66: 402-404.CrossRefPubMedPubMedCentral
44.
Gill PG, Gebski V, Snyder R, Burns I, Levi J, Byrne M, Coates A: Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. Ann Oncol. 1993, 4: 741-744.PubMed
45.
Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, Bhar P: Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009, 27: 3611-3619.CrossRefPubMed
46.
Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, Bhar P, McGuire JR, Iglesias J: Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival. Clin Breast Cancer. 2012, 12: 313-321.CrossRefPubMed
47.
Henderson IC, Allegra JC, Woodcock T, Wolff S, Bryan S, Cartwright K, Dukart G, Henry D: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol. 1989, 7: 560-571.PubMed
48.
Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Creagan ET, Hahn RG, Rubin J: Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. Am J Clin Oncol. 1982, 5: 155-160.CrossRefPubMed
49.
Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM: Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005, 23: 5542-5551.CrossRefPubMed
50.
Katsumata N, Watanabe T, Minami H, Aogi K, Tabei T, Sano M, Masuda N, Andoh J, Ikeda T, Shibata T, Takashima S: Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan clinical oncology group trial (JCOG9802). Ann Oncol. 2009, 20: 1210-1215.CrossRefPubMed
51.
Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G: Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol. 2000, 18: 1399-1411.PubMed
52.
Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G: Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study. Clin Breast Cancer. 2000, S15-S18.
53.
Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Cervek J, Fowst C, Polli A, Di Salle E, Massimini G, Piscitelli G: Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen: results of a double-blind randomised phase III trial. Eur J Cancer. 2000, 36: S86-S87.CrossRefPubMed
54.
Meier CR, Illiger HJ, Steder M, Janssen J, Deertz H, Braun M, Oeney HT, Deuss B, Kuchler T, Rotermund S: Weekly vinorelbine versus docetaxel for metastatic breast cancer after failing anthracycline treatment. Onkologie. 2008, 31: 447-453.CrossRefPubMed
55.
Muss HB, Paschold EH, Black WR, Cooper MR, Capizzi RL, Christian R, Cruz JM, Jackson DV, Stuart JJ, Richards F, White DR, Zekan PJ, Spurr CL, Pope E, Cose D, Morgan T, Wells HB: Megestrol acetate v tamoxifen in advanced breast cancer: a phase III trial of the Piedmont Oncology Association (POA). Semin Oncol. 1985, 12: 55-61.PubMed
56.
Muss HB, Wells HB, Paschold EH, Black WR, Cooper MR, Capizzi RL, Christian R, Cruz JM, Jackson DV, Powell BL: Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis–a phase III trial of the Piedmont Oncology Association. J Clin Oncol. 1988, 6: 1098-1106.PubMed
57.
O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004, 15: 440-449.CrossRefPubMed
58.
O'Shaughnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D, Rosso R, Mauriac L, Osterwalder B, Burger HU, Laws S: Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol. 2001, 12: 1247-1254.CrossRef
59.
Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol. 2000, 18: 724-733.PubMed
60.
Paridaens R, Dirix L, Beex L, Nooij M, Cufer T, Lohrisch C, Biganzoli L, Hoorebeeck I, Duchateau L, Lobelle JP, Piccart M: Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control. Clin Breast Cancer. 2000, S19-S21.
61.
Paridaens R, Dirix L, Beex L, Nooij M, Cufer T, Lohrisch C, Biganzoli L, Hoorebeeck I, Duchateau L, Lobelle JP, Piccart M: Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol. 2003, 14: 1391-1398.CrossRefPubMed
62.
Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, Piccart MJ, Bogaerts J, Therasse P: Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol. 2008, 26: 4883-4890.CrossRefPubMedPubMedCentral
63.
Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 2003, 21: 588-592.CrossRefPubMed
64.
Villalon AH, Ngelangel CA, Eufemio G, Laudico AV: Cyclophosphamide methotrexate 5-fluorouracil (CMF), vs. CMF megestrol acetate (CMF-M), vs. Megestrol acetate (M) for advanced breast cancer in Filipino women. Philipp J Intern Med. 1993, 31: 115-126.
65.
Chan S, Friedrich K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Mancha RG, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1999, 17: 2341-2354.PubMed
66.
Yardley DA, Burris HA, Spigel DR, Clark BL, Vazquez E, Shipley D, Barton J, Thompson D, Montes I, Greco FA, Hainsworth JD: A phase II randomized crossover study of liposomal doxorubicin versus weekly docetaxel in the first-line treatment of women with metastatic breast cancer. Clin Breast Cancer. 2009, 9: 247-252.CrossRefPubMed
67.
Cooper NJ, Peters J, Lai MC, Juni P, Wandel S, Palmer S, Paulden M, Conti S, Welton NJ, Abrams KR, Bujkiewicz S, Spiegelhalter D, Sutton AJ: How valuable are multiple treatment comparison methods in evidence-based health-care evaluation?. Value Health. 2011, 14: 371-380.CrossRefPubMed
68.
Cowan JD, Neidhart J, McClure S, Coltman CA, Gumbart C, Martino S, Hutchins LF, Stephens RL, Vaughan CB, Osborne CK: Randomized trial of doxorubicin, bisantrene and mitoxantrone in advanced breast cancer: a Southwest Oncology Group Study. J Natl Cancer Inst. 1991, 83: 1077-1084.CrossRefPubMed
69.
Cope S, Jansen JP: Quantitative summaries of treatment effect estimates obtained with network meta-analysis of survival curves to inform decision-making. BMC Med Res Methodol. 2013, 13: 147.CrossRefPubMedPubMedCentral
70.
Jansen JP, Trikalinos T, Cappelleri JC, Daw J, Andes S, Eldessouki R, Salanti G: Indirect treatment comparison/ network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision-making: an ISPOR-AMCP-NPC good practice task force report. Value Health. 2014, 17: 157-73.CrossRefPubMed
71.
Ades AE, Caldwell DM, Reken S, Welton NJ, Sutton AJ, Dias S: Evidence synthesis for decision making 7: a reviewer’s checklist. Med Decis Making. 2013, 33: 679-691.CrossRefPubMedPubMedCentral
72.
Mills EJ, Ioannidis JP, Thorlund K, Schünemann HJ, Puhan MA, Guyatt GH: How to use an article reporting a multiple treatment comparison meta-analysis. JAMA. 2012, 308: 1246-1253.CrossRefPubMed
73.
74.
Bachelot T, McCool R, Duffy S, Glanville J, Varley D, Fleetwood K, Zhang J, Jerusalem G: Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis. Breast Cancer Res Treat. 2014, 143: 125-133.CrossRefPubMed
75.
Spineli LM, Higgins JP, Cipriani A, Leucht S, Salanti G: Evaluating the impact of imputations for missing participant outcome data in a network meta-analysis. Clin Trials. 2013, 10: 378-388.CrossRefPubMed
76.
Cope S, Capkun-Niggli G, Gale R, Lassen C, Owen R, Ouwens MJ, Bergman G, Jansen JP: Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison. Value Health. 2012, 15: 524-533.CrossRefPubMed
77.
Donegan S, Williamson P, D'Alessandro U, Tudur Smith C: Assessing the consistency assumption by exploring treatment by covariate interactions in mixed treatment comparison meta-analysis: individual patient-level covariates versus aggregate trial-level covariates. Stat Med. 2012, 31: 3840-3857.CrossRefPubMed
78.
Saramago P, Sutton AJ, Cooper NJ, Manca A: Mixed treatment comparisons using aggregate and individual participant level data. Stat Med. 2012, 31: 3516-3536.CrossRefPubMed
79.
McCarron CE, Pullenayegum EM, Thabane L, Goeree R, Tarride JE: Bayesian hierarchical models combining different study types and adjusting for covariate imbalances: a simulation study to assess model performance. PLoS One. 2011, 6: e25635.CrossRefPubMedPubMedCentral
80.
McCarron CE, Pullenayegum EM, Thabane L, Goeree R, Tarride JE: The impact of using informative priors in a Bayesian cost-effectiveness analysis: an application of endovascular versus open surgical repair for abdominal aortic aneurysms in high-risk patients. Med Decis Making. 2013, 33: 437-450.CrossRefPubMed
81.
Schmitz S, Adams R, Walsh C: Incorporating data from various trial designs into a mixed treatment comparison model. Stat Med. 2013, 32: 2935-2949.CrossRefPubMed
82.
Turner RM, Spiegelhalter DJ, Smith GC, Thompson SG: Bias modelling in evidence synthesis. J R Stat Soc Ser A. 2009, 172: 21-47.CrossRef
Metadata
Title
A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer
Authors
Shannon Cope
Jie Zhang
Stephen Saletan
Brielan Smiechowski
Jeroen P Jansen
Peter Schmid
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2014
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/1741-7015-12-93

Other articles of this Issue 1/2014

BMC Medicine 1/2014 Go to the issue

Research article

Hospital admissions in relation to body mass index in UK women: a prospective cohort study

Correspondence

Strengths and weaknesses of guideline approaches to safeguard voluntary informed consent of patients within a dependent relationship

Question and Answer

Obesity and what we need do about it- an interview with John Wass

Research article

Comorbidity and dementia: a scoping review of the literature

Research article

Concordance between DSM-IV and DSM-5 criteria for delirium diagnosis in a pooled database of 768 prospectively evaluated patients using the delirium rating scale-revised-98

Opinion

Towards a framework for business model innovation in health care delivery in developing countries